Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea
- Authors
- Kim, Mimi; Yoon, Eileen Laurel; Cho, Seon; Lee, Chul-min; Kang, Bo-Kyeong; Park, Huiyul; Jun, Dae Won; Nah, Eun-Hee
- Issue Date
- Jul-2022
- Publisher
- WILEY
- Keywords
- advanced fibrosis; magnetic resonance imaging; metabolic dysfunction-associated fatty liver disease
- Citation
- LIVER INTERNATIONAL, v.42, no.7, pp.1536 - 154
- Indexed
- SCIE
SCOPUS
- Journal Title
- LIVER INTERNATIONAL
- Volume
- 42
- Number
- 7
- Start Page
- 1536
- End Page
- 154
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/173240
- DOI
- 10.1111/liv.15259
- ISSN
- 1478-3223
- Abstract
- Background & Aims
There are several reports on the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD). However, the prevalence of advanced hepatic fibrosis in MAFLD is largely unknown. We aimed to evaluate the prevalence of advanced fibrosis in MAFLD.
Methods
A total of 6775 subjects from nationwide 13 health check-up centres were included in this cross-sectional study. Fatty liver was evaluated using ultrasonography. Significant (≥F2) and advanced (≥F3) hepatic fibrosis were defined by MRE thresholds of 3.0 kPa (range: 2.99–3.65 kPa) and 3.6 kPa (range: 3.4–3.9 kPa) respectively. The sex- and age-standardized prevalence of MAFLD and hepatic fibrosis was estimated.
Results
The sex- and age-standardized prevalence of MAFLD was 33.9%. The prevalence of obesity (BMI ≥25 kg/m2) in MAFLD was 71.1%, and 79.0% of obese subjects had MAFLD. The prevalence of diabetes in MAFLD was 13.3%, and 73.6% of subjects with diabetes had MAFLD. The sex- and age-standardized prevalence of significant (≥F2) and advanced hepatic fibrosis (≥F3) amongst MAFLD was 9.7% (range: 3.0–9.8%) and 3.0% (range: 2.6–4.6%) respectively. The prevalence of advanced hepatic fibrosis in overweight/obese (group I), lean (group II) and diabetic (group III) MAFLD was 2.3%, 3.1% and 9.5% respectively.
Conclusion
The sex- and age-standardized prevalence of advanced fibrosis was 3.0% (range: 2.6–4.6%) in subjects with MAFLD.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
- 서울 의과대학 > 서울 영상의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/173240)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.